1. Total synthesis and antibacterial evaluation of Empetroxepins A and B and related analogs
- Author
-
Kyle E, Murphy, Marcia K, Thacher, Erin C, Young, Veronika, Mojik, and Amanda L, Wolfe
- Subjects
Biological Products ,Staphylococcus aureus ,Organic Chemistry ,Clinical Biochemistry ,Pharmaceutical Science ,Microbial Sensitivity Tests ,Biochemistry ,Anti-Bacterial Agents ,Oxepins ,Drug Discovery ,Escherichia coli ,Humans ,Molecular Medicine ,Molecular Biology ,Escherichia coli Infections ,Bacillus subtilis - Abstract
Empetroxepins A and B, which are 10,11-dihydrodibenz[b,f]oxepins produced by the Black Crowberry (Empetrum nigrum), displayed weak anti-tubercular activity upon isolation, but have not been explored for antibiotic activity despite their molecular similarity to other phenolic antibacterial natural products. Herein we detail the first total synthesis of Empetroxepins A and B via a selective demethylation strategy and antibacterial structure activity relationship (SAR) study of the natural products and related analogs. Empetroxepin A was found to be weakly active against susceptible strains of Staphylococcus aureus (SA) and Bacillus subtilis (BS) with a minimum inhibitory concentration (MIC) of 256 μg/mL against both bacteria, whereas Empetroxepin B was found to be weakly active against only BS (MIC = 256 μg/mL). Neither natural product was active against Escherichia coli (EC). Antibiotic activity was improved through derivatization of the 10,11-dihydrodibenz[b,f]oxepin core with the best compound of the SAR series, 9-chloro-10,11-dihydrodibenzo[b,f]oxepine-2,3,4-triol, having MICs of 8 μg/mL, 16 μg/mL, and 256 μg/mL against SA, BS, and EC respectively.
- Published
- 2022
- Full Text
- View/download PDF